- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Allergy
Volume 2013 (2013), Article ID 260518, 5 pages
Roles of IL-22 in Allergic Airway Inflammation
Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chiba City, Chiba 260-8670, Japan
Received 4 October 2012; Revised 21 January 2013; Accepted 22 January 2013
Academic Editor: Antoon J. M. van Oosterhout
Copyright © 2013 Koichi Hirose et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
IL-23- and IL-17A-producing CD4+ T cell (Th17 cell) axis plays a crucial role in the development of chronic inflammatory diseases. In addition, it has been demonstrated that Th17 cells and their cytokines such as IL-17A and IL-17F are involved in the pathogenesis of severe asthma. Recently, IL-22, an IL-10 family cytokine that is produced by Th17 cells, has been shown to be expressed at the site of allergic airway inflammation and to inhibit allergic inflammation in mice. In addition to Th17 cells, innate lymphoid cells also produce IL-22 in response to allergen challenge. Functional IL-22 receptor complex is expressed on lung epithelial cells, and IL-22 inhibits cytokine and chemokine production from lung epithelial cells. In this paper, we summarize the recent progress on the roles of IL-22 in the regulation of allergic airway inflammation and discuss its therapeutic potential in asthma.
Asthma is a chronic inflammatory disease that is accompanied by intense eosinophilic infiltration, goblet cell hyperplasia, and airway hyperreactivity (AHR) . In atopic asthma patients, it is well established that these features are mediated by antigen-specific Th2 cells and their cytokines including IL-4, IL-5, and IL-13 [2, 3]. In addition, several lines of evidence have shown that not only Th2 cell-derived cytokines but also Th17 cell-derived cytokines such as IL-17A and IL-17F are expressed in the airways in severe asthma patients, and that the levels of IL-17A and IL-17F in the airways are correlated with the severity of asthma, suggesting the involvement of Th17 cell-derived cytokines in the pathogenesis of severe asthma [4, 5]. Moreover, we and others have shown that Th17 cells are involved in the development of antigen-induced airway inflammation in murine asthma models [6–8]. Interestingly, recent studies have shown that IL-22, one of Th17 cell-derived cytokines, is detected in bronchoalveolar lavage fluid (BALF) in murine asthma models [8, 9]. Furthermore, it has been reported that the levels of IL-22 mRNA are increased in peripheral blood mononuclear cells in asthma patients [10, 11], and that the levels of IL-22 in sera tend to correlate with the severity of asthma . In this paper, we briefly summarize the roles of IL-22 in the regulation of allergic inflammation in asthma.
2. IL-22 and IL-22 Receptor
IL-22 is an IL-10 family cytokine that is originally identified from IL-9-stimulated T lymphoma cells and designated as IL-TIF (IL-10-related T cell-derived inducible factor) . Functional IL-22 receptor consists of IL-22R1 and IL-10R2, which are associated with tyrosine kinases Jak1 and Tyk2, respectively [14–16]. IL-22R ligation activates not only STAT pathways (STAT1, STAT3, and STAT5), but also JNK, ERK, and p38 MAP kinase pathways . In spite of the wide range activation of signaling pathways, however, STAT3-mediated signaling seems to be the major pathway in IL-22 signaling .
Interestingly, IL-22 possesses both proinflammatory and anti-inflammatory properties depending on environmental context. While a number of studies have shown that IL-22 plays protective roles in host defense against infectious diseases, some studies have shown that IL-22 is involved in the development of autoimmune diseases . In IL-23-induced dermatitis in mice, IL-22 is crucial for the induction of dermal inflammation and acanthosis . On the other hand, IL-22 plays a protective role in hepatitis and inflammatory bowel disease models [20, 21]. As described below, we and others have found that IL-22 attenuates antigen-induced allergic inflammation and Th2 cytokine production in the airways in mice presumably through the inhibition of cytokine and chemokine production from lung epithelial cells [22–24].
3. Roles of IL-22 in Murine Asthma Models
Recently, we and others have explored the roles of IL-22 in the pathogenesis of allergic airway inflammation and have shown that IL-22 expression is induced in the lung of antigen-sensitized mice upon antigen inhalation [8, 9, 22–24]. In addition, the administration of a neutralizing anti-IL-22 antibody significantly enhances antigen-induced infiltration of eosinophils, Th2 cytokine production in the airways, and AHR in mice [9, 22, 24]. On the other hand, intranasal administration of recombinant IL-22 attenuates antigen-induced eosinophil infiltration into the airways, even if IL-22 is administered into the airways after the induction of allergic airway inflammation [22, 24]. Moreover, it has been demonstrated that enforced expression of IL-22 by gene delivery suppresses eosinophilic airway inflammation and Th2 cytokine production in the airways in mice . Consistent with these findings, Taube et al. have reported that antigen-induced allergic inflammation is enhanced in IL-22-deficient mice . These findings suggest that IL-22 has a protective role for the development of antigen-induced airway inflammation in mice during the effector phase. On the other hand, Besnard et al. have shown that IL-22 also plays a crucial role in antigen sensitization in a murine asthma model in which mice were sensitized with antigens subcutaneously . Considering the contribution of percutaneous priming for the development of atopic march, a progression from eczema to allergic rhinitis and asthma [26, 27], their finding may suggest that IL-22 plays a role in percutaneous sensitization and thus the development of asthma in patients with eczema. Taken together, based on these murine studies, we propose that IL-22 has a double-edged nature in allergic airway inflammation, depending on the timing or the site of its expression.
IL-22-binding protein (IL-22BP), which is highly homologous to the extracellular domain of IL-22 receptor, is considered as an endogenous antagonist for IL-22 . Interestingly, IL-22BP is highly expressed in lung and colon, where IL-22 exhibits a regulatory role . Moreover, by using IL-22BP-deficient mice, Huber et al. have recently demonstrated that the downregulation of IL-22BP, thereby increasing the ratio of IL-22/IL-22BP, is induced during intestinal tissue damage and thus contributes to the protective properties of IL-22 , suggesting that IL-22BP functions as an intrinsic inhibitor of IL-22 in the colon. However, it remains unknown whether IL-22BP plays a role in allergic airway inflammation in mice and whether IL-22BP has equivalent properties in humans.
4. Cellular Sources of IL-22 in the Lung in Murine Asthma Models
It has been reported that not only CD4+ T cells including Th17 cells and Th22 cells, but also some populations of innate immune cells including NK cells, dendritic cells (DCs), and lymphoid tissue inducer-like cells (LTi-like cells) are capable of producing IL-22 [30–35]. We have shown that the majority of IL-22-producing cells at the site of allergic airway inflammation are CD4+ T cells and that one third of the IL-22-producing CD4+ T cells produce IL-17A , suggesting that some of IL-22-producing CD4+ T cells in a murine asthma model are Th17 cells. We have also shown that NK cells, DCs, and LTi-like cells do not express IL-22 mRNA in the lung in the murine asthma model . In contrast, Taube et al. have reported that RORγt-expressing LTi-like cells are the major cellular sources of IL-22 in the lung in a different murine model of asthma . In this regard, a recent study in a murine intestinal infection model has shown that IL-22 produced by CD4+ T cells contributes to late-phase responses to an intestinal pathogen, while IL-22 produced by innate cells plays a critical role in early-phase responses . In analogy to these findings, IL-22 produced by LTi-like cells and that produced by CD4+ T cells may play a distinct role in allergic airway inflammation depending on the phase of responses.
5. Mechanisms Underlying IL-22-Mediated Inhibition of Allergic Airway Inflammation
The functional IL-22 receptor is a heterodimer of IL-22R1 and IL-10R2 and previous studies have shown that whereas IL-10R2 is ubiquitously expressed in various cells, the expression of IL-22R1 is restricted to nonimmune cells [14, 15]. Indeed, in a murine model of asthma, IL-22R1 is expressed in lung epithelial cells, but not in hematopoietic cells in the lung including alveolar macrophages, CD4+ T cells, and CD8+ T cells . While a previous report suggested that DCs mediate the inhibitory function of IL-22 in mice , we failed to detect IL-22R1 mRNA expression in bone marrow-derived DCs . Moreover, Nakagome et al. have reported that enforced expression of IL-22 does not affect DC functions in mice , supporting the notion that DCs are not direct targets of IL-22. Our finding that IL-22 phosphorylates STAT3, a signal transducer of IL-22, in lung epithelial cell line  further suggests that functional IL-22 receptor complex is expressed on lung epithelial cells and that direct targets of IL-22 in a murine model of asthma are lung epithelial cells.
Recently, there has been great progress in understanding the mechanism by which lung epithelial cells regulate the development of allergic inflammation . Lung epithelial cells have been shown to produce several cytokines which promote Th2 responses and chemokines which attract immune cells into the lung in both mice and humans . Importantly, anti-IL-22 antibody treatment significantly enhances the expression of IL-25, one of the epithelial cell-derived cytokines which promote Th2 responses, in the BALF in a murine model of asthma . In addition, it has been shown that anti-IL-22 antibody enhances the production of IL-33, which also promotes Th2 responses, in different murine models of asthma [24, 37]. Furthermore, IL-22 has been shown to inhibit the expression of CCL17, which induces the recruitment of activated T cells into the lung, in a murine Clara cell line  as well as in a murine model of asthma . These findings suggest that IL-22 may inhibit antigen-induced airway inflammation by suppressing cytokine and chemokine production from lung epithelial cells.
The fact that IL-22 enhances the expression of host-defense peptides in epithelial cells is now widely accepted. In addition, it has recently been demonstrated that IL-22 enhances mucosal barrier function by protecting intestinal stem cells during inflammatory intestinal damage . Several lines of evidence have suggested that the disruption of barrier function of lung is associated with the development of allergic airway inflammation by facilitating the entry of allergens into the tissue [39, 40]. These findings raise the possibility that IL-22 may suppress the development of allergic airway inflammation by enhancing the barrier function of airway epithelial cells.
6. IL-22 and Asthmatic Patients
It has been reported that IL-22 levels are increased in the sera of asthma patients and are positively correlated with disease severity [11, 12, 24]. The majority of IL-22-producing cells in peripheral blood of asthma patients are CD4+ CCR6+ CD161+ cells , suggesting that Th17 cells are the main producer of IL-22. In contrast, it has been reported that the majority of IL-22-producing CD4+ T cell lines which are generated from lung biopsy specimens of asthma patients produce IFN-γ . The reason for the discrepancy is at present unclear and further studies to verify the cellular source of IL-22 in asthma patients are required.
Regarding the function of IL-22 in asthma patients, Pennino et al. have recently shown that IL-22 inhibits IFN-γ-induced expression of proinflammatory chemokines and adhesion molecules in human bronchial epithelial cells . They have also shown that the levels of IL-22 in the BALF of asthma patients are inversely correlated with the levels of proinflammatory chemokines, suggesting the protective roles of IL-22 in asthma patients . On the other hand, it has been shown that IL-22R1 is expressed on not only lung epithelial cells but also airway smooth muscle cells (ASMCs) in humans and that IL-22 enhances the proliferation and migration of human ASMCs [43–45], suggesting that IL-22 may involve in smooth muscle cell hyperplasia, a key pathological feature of asthma, in human airways. Taken together, these human studies suggest that IL-22 plays inhibitory roles in the development of allergic airway inflammation in asthma patients, but it could promote airway remodeling if its expression is uncontrolled during the resolution phase of allergic inflammation.
7. Concluding Remarks
In this paper, we outlined the roles of IL-22 in the development of allergic airway inflammation. Based on the findings of murine asthma models, IL-22 is produced by Th17 cells and LTi-like cells at the site of allergic airway inflammation and attenuates eosinophilic inflammation and AHR, presumably by inhibiting cytokine and chemokine production from lung epithelial cells (Figure 1). In asthma patients, however, excessive production of IL-22 may lead to the progression of airway remodeling by enhancing the proliferation and migration of ASMCs. Further studies to elucidate the precise function of IL-22 at different stages of asthma pathogenesis will provide a great benefit for the development of a novel therapeutic approach for asthma.
This work was partly supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, The Japanese Government, and by Global COE Program (Global Center for Education and Research in Immune System Regulation and Treatment), MEXT, Japan.
- W. Eder, M. J. Ege, and E. Von Mutius, “The asthma epidemic,” The New England Journal of Medicine, vol. 355, no. 21, pp. 2226–2235, 2006.
- S. T. Holgate, “Innate and adaptive immune responses in asthma,” Nature Medicine, vol. 18, pp. 673–683, 2012.
- D. T. Umetsu, J. J. McIntire, O. Akbari, C. Macaubas, and R. H. Dekruyff, “Asthma: an epidemic of dysregulated immunity,” Nature Immunology, vol. 3, no. 8, pp. 715–720, 2002.
- J. Chakir, J. Shannon, S. Molet et al., “Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression,” Journal of Allergy and Clinical Immunology, vol. 111, no. 6, pp. 1293–1298, 2003.
- S. Molet, Q. Hamid, F. Davoine et al., “IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines,” Journal of Allergy and Clinical Immunology, vol. 108, no. 3, pp. 430–438, 2001.
- H. Wakashin, K. Hirose, Y. Maezawa et al., “IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 10, pp. 1023–1032, 2008.
- X. O. Yang, H. C. Seon, H. Park et al., “Regulation of inflammatory responses by IL-17F,” Journal of Experimental Medicine, vol. 205, no. 5, pp. 1063–1075, 2008.
- S. Lajoie, I. P. Lewkowich, Y. Suzuki et al., “Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma,” Nature Immunology, vol. 11, no. 10, pp. 928–935, 2010.
- B. Schnyder, C. Lima, and S. Schnyder-Candrian, “Interleukin-22 is a negative regulator of the allergic response,” Cytokine, vol. 50, no. 2, pp. 220–227, 2010.
- V. Farfariello, C. Amantini, M. Nabissi et al., “IL-22 mRNA in peripheral blood mononuclear cells from allergic rhinitic and asthmatic pediatric patients,” Pediatric Allergy and Immunology, vol. 22, no. 4, pp. 419–423, 2011.
- J. Zhu, Y. Cao, K. Li et al., “Increased expression of aryl hydrocarbon receptor and interleukin 22 in patients with allergic asthma,” Asian Pacific Journal of Allergy and Immunology, vol. 29, pp. 266–272, 2011.
- Y. Zhao, J. Yang, Y. D. Gao, and W. Guo, “Th17 immunity in patients with allergic asthma,” International Archives of Allergy and Immunology, vol. 151, no. 4, pp. 297–307, 2010.
- L. Dumoutier, J. Louahed, and J. C. Renauld, “Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9,” Journal of Immunology, vol. 164, no. 4, pp. 1814–1819, 2000.
- G. F. Sonnenberg, L. A. Fouser, and D. Artis, “Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces,” Advances in Immunology, vol. 107, pp. 1–29, 2010.
- K. Wolk and R. Sabat, “Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells,” Cytokine and Growth Factor Reviews, vol. 17, no. 5, pp. 367–380, 2006.
- D. Lejeune, L. Dumoutier, S. Constantinescu, W. Kruijer, J. J. Schuringa, and J. C. Renauld, “Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line: pathways that are shared with and distinct from IL-10,” Journal of Biological Chemistry, vol. 277, no. 37, pp. 33676–33682, 2002.
- G. Pickert, C. Neufert, M. Leppkes et al., “STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing,” Journal of Experimental Medicine, vol. 206, no. 7, pp. 1465–1472, 2009.
- H. F. Pan, X. P. Li, S. G. Zheng, and D. Q. Ye, “Emerging role of interleukin-22 in autoimmune diseases,” Cytokine and Growth Factor Reviews. In press.
- Y. Zheng, D. M. Danilenko, P. Valdez et al., “Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis,” Nature, vol. 445, no. 7128, pp. 648–651, 2007.
- L. A. Zenewicz, G. D. Yancopoulos, D. M. Valenzuela, A. J. Murphy, M. Karow, and R. A. Flavell, “Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation,” Immunity, vol. 27, no. 4, pp. 647–659, 2007.
- L. A. Zenewicz, G. D. Yancopoulos, D. M. Valenzuela, A. J. Murphy, S. Stevens, and R. A. Flavell, “Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease,” Immunity, vol. 29, no. 6, pp. 947–957, 2008.
- K. Takahashi, K. Hirose, S. Kawashima et al., “IL-22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-induced eosinophilic airway inflammation,” Journal of Allergy and Clinical Immunology, vol. 128, pp. 1067–1076, 2011.
- C. Taube, C. Tertilt, G. Gyulveszi et al., “IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease,” PLoS ONE, vol. 6, Article ID e21799, 2011.
- A. G. Besnard, R. Sabat, L. Dumoutier et al., “Dual role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A,” American Journal of Respiratory and Critical Care Medicine, vol. 183, pp. 1153–1163, 2011.
- K. Nakagome, M. Imamura, K. Kawahata et al., “High expression of IL-22 suppresses antigen-induced immune responses and eosinophilic airway inflammation via an IL-10-associated mechanism,” Journal of Immunology, vol. 187, pp. 5077–5089, 2011.
- F. C. Van Reijsen, C. A. F. M. Bruijnzeel-Koomen, F. S. Kalthoff et al., “Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 90, no. 2, pp. 184–193, 1992.
- J. M. Spergel, “From atopic dermatitis to asthma: the atopic march,” Annals of Allergy, Asthma and Immunology, vol. 105, no. 2, pp. 99–106, 2010.
- L. Dumoutier, D. Lejeune, D. Colau, and J. C. Renauld, “Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22,” Journal of Immunology, vol. 166, no. 12, pp. 7090–7095, 2001.
- S. Huber, N. Gagliani, L. A. Zenewicz et al., “IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine,” Nature, vol. 491, pp. 259–263, 2012.
- M. Cella, A. Fuchs, W. Vermi et al., “A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity,” Nature, vol. 457, no. 7230, pp. 722–725, 2009.
- T. Duhen, R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto, “Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells,” Nature Immunology, vol. 10, no. 8, pp. 857–863, 2009.
- S. C. Liang, X. Y. Tan, D. P. Luxenberg et al., “Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides,” Journal of Experimental Medicine, vol. 203, no. 10, pp. 2271–2279, 2006.
- H. Takatori, Y. Kanno, W. T. Watford et al., “Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22,” Journal of Experimental Medicine, vol. 206, no. 1, pp. 35–41, 2009.
- K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat, “IL-22 increases the innate immunity of tissues,” Immunity, vol. 21, no. 2, pp. 241–254, 2004.
- R. Basu, D. B. O’Quinn, D. J. Silberger et al., “Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria,” Immunity, vol. 37, pp. 1061–1075, 2012.
- B. N. Lambrecht and H. Hammad, “The airway epithelium in asthma,” Nature Medicine, vol. 18, pp. 684–692, 2012.
- A. P. Moreira, K. A. Cavassani, U. B. Ismailoglu et al., “The protective role of TLR6 in a mouse model of asthma is mediated by IL-23 and IL-17A,” The Journal of Clinical Investigation, vol. 121, pp. 4420–4432, 2011.
- A. M. Hanash, J. A. Dudakov, G. Hua et al., “Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease,” Immunity, vol. 37, pp. 339–350, 2012.
- E. J. Swindle, J. E. Collins, and D. E. Davies, “Breakdown in epithelial barrier function in patients with asthma: identification of novel therapeutic approaches,” Journal of Allergy and Clinical Immunology, vol. 124, no. 1, pp. 23–34, 2009.
- C. Xiao, S. M. Puddicombe, S. Field et al., “Defective epithelial barrier function in asthma,” Journal of Allergy and Clinical Immunology, vol. 128, pp. 549–556, 2011.
- L. Cosmi, L. Maggi, V. Santarlasci et al., “Identification of a novel subset of human circulating memory CD4+ T cells that produce both IL-17A and IL-4,” Journal of Allergy and Clinical Immunology, vol. 125, no. 1–3, pp. 222.e4–230.e4, 2010.
- D. Pennino, P. K. Bhavsar, R. Effner et al., “IL-22 suppresses IFN-g-mediated lung inflammation in asthmatic patients,” Journal of Allergy and Clinical Immunology. In press.
- Y. Chang, L. Al-Alwan, P. A. Risse et al., “TH17 cytokines induce human airway smooth muscle cell migration,” Journal of Allergy and Clinical Immunology, vol. 127, no. 4, pp. 1046.e2–1053.e2, 2011.
- M. Kudo, A. C. Melton, C. Chen et al., “IL-17A produced by ab T cells drive airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction,” Nature Medicine, vol. 18, pp. 547–554, 2012.
- Y. Chang, L. Al-Alwan, P. A. Risse et al., “Th17-associated cytokines promote human airway smooth muscle cell proliferation,” The FASEB Journal, vol. 26, pp. 5152–5160, 2012.